Physician profile

Mark H Moriarty

Orthopaedic Surgery · Franklin, NC

NPI 1851488399

$736.41

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$109.30

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Smith+Nephew, INC. $317.10 2019-2024 Evos, Real Intelligence, Conquest Fn
Depuy Synthes Sales INC. $242.61 2021
Heraeus Medical, LLC. $62.78 2019-2020
Ethicon US, LLC $35.39 2020
Djo, LLC $25.78 2021
Zimmer Biomet Holdings, INC. $25.38 2024 Tricera Handpiece
Sanofi-Aventis U.S. LLC $15.49 2020
Janssen Pharmaceuticals, INC $11.88 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark H Moriarty

$736.41

in general payments reported 2019-2025

Years
2019-2024
Top company
Smith+Nephew, INC.

https://glasscript.com/doctor/1127949/mark-h-moriarty

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.